![]() Primary cutaneous lymphomas are currently classified by the European Organization for Research and Treatment of Cancer (EORTC) classification or the World Health Organization (WHO) classification, but both systems have shortcomings. Patients treated with mogamulizumab were more likely to observe a 2-grade improvement in burning or stinging skin (OR = 1.62, CI: 1.013–2.591, P < 0.05) and more likely to observe improvement in painful skin (OR = 1.78, CI: 1.045–3.021, P < 0.05).Ĭonclusions: Single item analyses suggest a mogamulizumab symptom benefit during treatment compared to vorinostat for items on the skin symptoms of Skindex-29 and toxicity bother items of FACT-G. Forest plots of odds ratios (OR) characterized the likelihood of a 1- and 2-grade categorical improvement on individual items. Item analyses used longitudinal generalized estimation equations of the post-baseline, treated period assessments to estimate likelihood of improvement. Pruritus was assessed with the ItchyQoL (measures symptoms, functioning, and emotions) and Likert Scale for level of itching. Methods: Health-related quality of life was assessed during the MAVORIC clinical trial of mogamulizumab for treatment of cutaneous T-cell lymphomas compared to vorinostat using the Skindex-29 (measures emotions, symptoms, and functioning) and Functional Assessment of Cancer Therapy – General (FACT-G) (assesses physical, social/family, emotional, and functional well-being). The purpose of this study was to determine whether patient-reported outcome individual items on skin symptoms and toxicity bother show significant treatment differences for patients with mycosis fungoides or Sézary syndrome. Background: Cutaneous T-cell lymphomas, including mycosis fungoides or Sézary syndrome, are rare non-Hodgkin lymphomas that can be serious and life-threatening with significant morbidity and impaired quality of life. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2022
Categories |